Full Text
Full text is available in PDF
Official Journal of Research Center for Gastroenterology and Liver Diseases
e-ISSN 1735-3408
p-ISSN 1735-143X
Comparison of Intra-Arterial Chemotherapy with Gemcitabine or Floxuridine Followed by TACE with Oxaliplatine
Authors
Hao Ming Zhi1, Chen Qiang2,*, Lin Hai Lan1, Wu Hui3, Chen Qi Zhong3, Li Jian Cheng3, Zheng Jian Xiong3, Ye Yun Bin3
1Department of Interventional Radiology, Fujian Provincial Tumor Hospital, Fujian, P.R.China
2Department of Medical Oncology, Fujian Provincial Tumor Hospital, cqiang8@pub5.fz.fj.cn, Fujian Province, P.R.China
3Department of Medical Oncology, Fujian Provincial Tumor Hospital, Fujian Province, P.R.China
*Corresponding Author: Department of Medical Oncology, Fujian Provincial Tumor Hospital, cqiang8@pub5.fz.fj.cn, Fujian Province, P.R.China. Tel: +86 0591 8366 0063. Fax: +86 0591 8366 0063. Email: cqiang8@pub5.fz.fj.cn
Published online:Dec 31, 2009
Article type:Research Article
Received:Jul 30, 2009
Accepted:Oct 12, 2009
How to Cite:Zhi H, Qiang C, Lan L, Hui W, Zhong C, et al. Comparison of Intra-Arterial Chemotherapy with Gemcitabine or Floxuridine Followed by TACE with Oxaliplatine. Hepat Mon. 2009;9(4):. doi:
Abstract
Background and Aims: To investigate the efficacy and safety of a gemcitabine plus oxaliplatin combination regimen and a floxuridine plus oxaliplatin combination regimen used in transcatheter arterial chemoembolization for patients with inoperable hepatocellular carcinoma (HCC).
Methods: From October 2005 to October 2008, 122 chemonaïve patients with newly diagnosed, inoperable HCC were randomized into a gemcitabine plus oxaliplatin combination regimen group (GO group) or a floxuridine plus oxaliplatin combination regimen group (FO group). The GO group was treated with 1,600 mg of gemcitabine and 200 mg of oxaliplatin, and the FO group was treated with 1,000 mg of floxuridine and 200 mg of oxaliplatin. Both groups were treated with glutin and iodolipol as the embolic agent in the transcatheter arterial chemoembolization (TACE).
Results: The progression-free survival, the median survival period, and the median time to progress had no significant difference between the two groups. However, there was a significant difference in the incidence of grade 3/4 thrombocytopenia between the two groups (P = 0.002). Grade 3/4 hematologic toxicity was observed only in the GO group. One patient (1.7%) with grade 3/4 leukopenia and 6 patients (10%) with grade 3/4 thrombocytopenia were observed. A multivariate analysis revealed that the Eastern Cooperative Oncology Group (ECOG) scores and portal vein thrombosis were the only independent prognostic factors that affected progression-free survival.
Conclusions: The floxuridine plus oxaliplatin combination regimen was tolerated better than the gemcitabine plus oxaliplatin combination regimen used in TACE.
Highlights
Copyright
© 2009, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
16
Jan
2017
Hepatic Arterial Infusion Chemotherapy with Cisplatin for TACE-Refractory or -Ineligible Hepatocellular Carcinoma with Child-Pugh Score of 8 or Above
Michihisa Moriguchi,
Takeshi Aramaki,
Kiichiro Yoza,
Kenji Iwai,
Rui Sato,
Koiku Asakura
,et al.Moriguchi M, Aramaki T, Yoza K, Iwai K, Sato R, et al. Hepatic Arterial Infusion Chemotherapy with Cisplatin for TACE-Refractory or -Ineligible Hepatocellular Carcinoma with Child-Pugh Score of 8 or Above. Hepat Mon. 2017;17(2):e43627. doi: https://doi.org/10.5812/hepatmon.43627
16
Jul
2025
Prophylactic Interventional Therapy After Hepatectomy for Primary Liver Cancer: A Clinical Comparative Study of FOLFOX-HAIC and TACE
Shuai He,
Wenjie Lou,
Junwei Zhao,
Yuxing Ni,
Haijun Du,
Xiyuan Yang
He S, Lou W, Zhao J, Ni Y, Du H, et al. Prophylactic Interventional Therapy After Hepatectomy for Primary Liver Cancer: A Clinical Comparative Study of FOLFOX-HAIC and TACE. Hepat Mon. 2025;25(1):e160901. doi: https://doi.org/10.5812/hepatmon-160901
23
Feb
2026
Efficacy and Safety Analysis of Local-Systemic Combined Therapy Versus Systemic Therapy Alone in TACE-Resistant Hepatocellular Carcinoma Patients
Peijie Xia,
Aibing Xu,
Siyuan Tian,
Honghua Huang,
Miao Ouyang,
Shengnan Huang
,et al.Xia P, Xu A, Tian S, Huang H, Ouyang M, et al. Efficacy and Safety Analysis of Local-Systemic Combined Therapy Versus Systemic Therapy Alone in TACE-Resistant Hepatocellular Carcinoma Patients. Hepat Mon. 2026;26(1):e168214. doi: https://doi.org/10.5812/hepatmon-168214
24
May
2023
Transarterial Chemoembolization for Refractory Hepatocellular Carcinoma Following Anti-angiogenic Therapy Combined with Immune Checkpoint Inhibitors: A Retrospective Single-center Analysis
Qimin Zhang,
Jiajia Xu,
Mengye Xiong,
Yiqing Tan
Zhang Q, Xu J, Xiong M, Tan Y. Transarterial Chemoembolization for Refractory Hepatocellular Carcinoma Following Anti-angiogenic Therapy Combined with Immune Checkpoint Inhibitors: A Retrospective Single-center Analysis. I J Radiol. 2023;20(2):e133070. doi: https://doi.org/10.5812/iranjradiol-133070
28
Dec
2014
Transcatheter Arterial Chemoembolization Therapy for Patients With Unresectable Hepatocellular Carcinoma
Kavous Firouznia,
Hossein Ghanaati,
Seyed Moayed Alavian,
Payam Azadeh,
Mohsen Nasiri Toosi,
Arya Haj Mirzaian
,et al.Firouznia K, Ghanaati H, Alavian SM, Azadeh P, Nasiri Toosi M, et al. Transcatheter Arterial Chemoembolization Therapy for Patients With Unresectable Hepatocellular Carcinoma. Hepat Mon. 2014;14(12):e25792. doi: https://doi.org/10.5812/hepatmon.25792
Cited by
- Scopus by DOI: 0
Last Update: 3 weeks ago
- Scopus by Title: 4
Last Update: 3 weeks ago
- Scopus by Title (Ref): 0
Last Update: 3 weeks ago
- CrossRef: 0
Last Update: 7 hours ago
- OpenAlex: 0
Last Update: 1 day ago
- OpenCitations: 0
Last Update: 4 days ago
Comments
Number of Comments:0